No Placebo-Only Group

Patients will have immune cells collected and then expanded outside of the body. Patients will undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation. Three days following the transplant, patients will receive an infusion of a large number of expanded immune cells. The goal of the study will be to determine the safety as well as potential efficacy of this treatment.

T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant

T Cell Immunotherapy for Multiple Myeloma

This study is evaluating whether a treatment that uses immune cells to fight cancer is safe and effective.

I have been diagnosed with POEMS syndrome, non-secretory myeloma, plasma cell leukemia, or amyloidosis.

I am approved for a stem cell transplant using my own cells.

I am fully active or can carry out light work.

My multiple myeloma has worsened or returned after treatment.

I have had a stem cell transplant before.

I have an autoimmune disease that needs treatment with medication.

My condition was diagnosed as Stage II or III.

I've had at least 3 cycles of chemotherapy or 3 months of high-dose steroids without my disease getting worse.

I do not have severe heart, lung, kidney, liver, stomach, nerve, or mental health issues.

I have not used corticosteroids in the last 21 days.

I haven't taken antibiotics or antivirals in the last week.

I have not had cancer, other than skin cancer or multiple myeloma, in the last 5 years.

I have been diagnosed with multiple myeloma.

I am able to have children, tested negative for pregnancy, and will use birth control for 6 months.

T Cell Immunotherapy

Pivotal Trial

This is a Phase 3 study in patients with melanoma that has spread to the lymph nodes (stage III), and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

Vaccine Therapy for Patients With Stage III Melanoma

Vaccine Therapy for Stage III Melanoma

This study is evaluating whether a vaccine can prevent or slow the recurrence of melanoma.

All visible signs of my disease have been surgically removed.

I am not on medications or therapies that weaken my immune system.

CancerVax™ Vaccine

This is a Phase III study in patients with melanoma that has spread to the lymph nodes and/or a distant organ, and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

Vaccine Therapy for Patients With Stage IV Melanoma

Cancer Vaccine for Melanoma

All visible signs of my disease were removed with surgery.

I am not on any treatments that weaken my immune system.

This randomized phase III trial studies different chemotherapy and radiation therapy regimens to compare how well they work in treating young patients with newly diagnosed, previously untreated, high-risk medulloblastoma. Drugs used in chemotherapy, such as vincristine sulfate, cisplatin, cyclophosphamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Carboplatin may make tumor cells more sensitive to radiation therapy. It is not yet known which chemotherapy and radiation therapy regimen is more effective in treating brain tumors.

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

Chemotherapy + Radiation for Medulloblastoma

This study is evaluating whether a combination of chemotherapy and radiation therapy is more effective than either treatment alone in treating young patients with newly diagnosed, previously untreated, high-risk medulloblastoma.

I should be careful with certain kidney-damaging medications.

My cancer has not spread to distant organs (not M4).

I have been newly diagnosed with medulloblastoma and have not received any treatment.

I have a specific type of brain tumor called diffusely anaplastic medulloblastoma.

I am not taking strong drugs that affect liver enzymes.

My seizure medication will be monitored while I receive cisplatin.

I have not had chemotherapy or radiation therapy before.

I am not taking corticosteroids with my chemotherapy.

I have had a brain MRI with contrast before surgery.

My kidney function, measured by creatinine levels, is appropriate for my age and gender.

I have had a head MRI with contrast after surgery.

I have had an MRI of my spine with a special dye.

Carboplatin

Cisplatin

Cyclophosphamide

Radiation Therapy

Vincristine Sulfate

This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. After a common induction therapy, patients were risk assigned and eligible for one or both post-induction randomizations: Escalating dose Methotrexate versus High Dose Methotrexate in Interim Maintenance therapy, No Nelarabine versus Nelarabine in Consolidation therapy. T-ALL patients are risk assigned as Low Risk, Intermediate Risk or High Risk. Low Risk patients are not eligible for the Nelarabine randomization, Patients with CNS disease at diagnosis were assgined to receive High Dose Methotrexate, patients who failed induction therapy were assigned to receive Nelarabine and High Dose Methotrexate. T-LLy patients were all assigned to escalating dose Methotrexate and were risk assigned as Standard Risk, High Risk and induction failures. Standard risk patients did not receive nelarabine, High risk T-LLy patients were randomized to No Nelarabine versus Nelarabine, and Induction failures were assigned to receive Nelarabine.

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Combination Chemotherapy for T-Cell Leukemia/Lymphoma

This study is evaluating whether a combination of drugs is more effective than a single drug in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.

My T-NHL does not include specific types like B-precursor lymphoblastic lymphoma or involve the brain/testicles.

I have not had chemotherapy, except for steroids or IT cytarabine.

My leukemia is classified as T-ALL based on specific cell markers.

I have been newly diagnosed with T-ALL or T-NHL at stage II-IV.

I've had IT chemotherapy with cytarabine for convenience before joining.

I have T-NHL or T-ALL and may need steroids before starting treatment, affecting my risk classification.

I've had emergency chest radiation up to 600 cGy for airway issues.

I haven't taken seizure medications or had significant nerve damage in the last 2 years.

Asparaginase

Daunorubicin Hydrochloride

Dexamethasone

Doxorubicin Hydrochloride

Mercaptopurine

Methotrexate

Nelarabine

Pegaspargase

Prednisone

Thioguanine

This randomized phase III trial studies octreotide acetate and recombinant interferon alfa-2b to see how well it works compared to octreotide acetate and bevacizumab in treating patients with high-risk neuroendocrine tumors that have spread to other places in the body (metastatic) or spread from where it started to nearby tissue or lymph nodes (locally advanced). Octreotide acetate and recombinant interferon alfa-2b may interfere with the growth of tumor cells and slow the growth of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving octreotide acetate together with recombinant interferon alfa-2b is more effective than giving octreotide acetate together with bevacizumab in treating patients with neuroendocrine tumor.

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Octreotide + Interferon/Bevacizumab for Neuroendocrine Tumors

This study is evaluating whether octreotide acetate and recombinant interferon alfa-2b are more effective than octreotide acetate and bevacizumab in treating patients with high-risk neuroendocrine tumors.

My blood clotting tests are within normal ranges.

I have had treatments targeting specific cancer growth factors before.

My condition is high risk due to its progression, symptoms, or number of lesions.

My cancer cannot be removed by surgery and is a type of slow or moderately growing neuroendocrine tumor.

My cancer has not spread to the bones only.

I have not been treated with interferon, bevacizumab, or any drugs targeting VEGF.

I have fully recovered from my previous surgery.

I have not had any other cancer types, except for certain allowed cases.

I can take care of myself and am up and about more than 50% of my waking hours.

My pathology report identifies my cancer as a type of neuroendocrine tumor.

I do not have any excluded medical conditions.

I have had a procedure to block blood flow to my liver.

My medical center will provide my scans and tissue samples for review.

I have had one previous chemotherapy treatment.

Bevacizumab

Octreotide Acetate

Recombinant Interferon Alfa-2b

This randomized phase III trial studies whether changes in diet and physical activity can increase the length of survival without the return of cancer (progression-free survival) compared with usual care in patients with previously treated stage II, III, or IV ovarian, fallopian tube, or primary peritoneal cancer. A healthy diet and physical activity program and counseling may help patients make healthier lifestyle choices. It is not yet known whether changes in diet and exercise may help increase progression-free survival in patients with previously treated cancer.

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Lifestyle Changes for Ovarian Cancer

This study is evaluating whether changes in diet and physical activity can increase the length of survival without the return of cancer.

I am currently being treated for or recently finished treatment for advanced ovarian, fallopian tube, or peritoneal cancer.

I haven't had any cancer except for non-melanoma skin cancer or very early uterine cancer in the last 5 years.

I finished my initial cancer treatments between 6 weeks and 6.5 months ago and am now in complete remission.

My condition severely limits my daily activities.

Criterion: People who only eat plant-based foods.

My cancer is one of the specific types listed, like serous or endometrioid adenocarcinoma.

I was diagnosed with ovarian, fallopian tube, or peritoneal cancer at an advanced stage.

You have taken part in a marathon, triathlon, or similar long-distance event in the past 2 years.

I can take care of myself but might not be able to do heavy physical work.

My cancer markers and scans showed no signs of cancer after treatment.

You are expected to live for less than one year.

You have a body mass index (BMI) lower than 20 kg/m^2.

I am not willing to stop my weight loss program or medications.

I have been diagnosed with early-stage ovarian, fallopian tube, or peritoneal cancer.

Behavioral Dietary Intervention

Compliance Monitoring

Counseling

Educational Intervention

Exercise Intervention

This randomized phase III trial studies radiation therapy to see how well it works with or without trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether radiation therapy is more effective with or without trastuzumab in treating ductal carcinoma in situ.

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Radiation Therapy + Trastuzumab for Breast Cancer

This study is evaluating whether radiation therapy is more effective with or without trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy.

I am fully active or restricted in physically strenuous activity but can do light work.

I have been cancer-free for over 5 years and at low risk of it coming back.

I have suspicious masses or calcifications that have not been biopsied.

My blood pressure is not controlled by medication.

My breast cancer is invasive, even if it's very small.

My DCIS is HER2-positive based on specialized testing.

I have received whole breast radiation before being considered for this study.

My surgery removed all the cancerous cells.

My cancer has spread to nearby lymph nodes.

My breast cancer is present in more than one area.

My lymph nodes are cancer-free or only microscopically affected.

I have received anthracycline chemotherapy before.

My cancer's hormone receptor status has been tested.

I had surgery to remove a non-invasive breast cancer.

My last surgery for DCIS was within the last 4 months.

I don't have any health conditions that would stop me from getting certain cancer treatments or attending follow-up visits.

I do not have heart conditions that would prevent me from taking certain cancer treatments.

Trastuzumab

Whole Breast Irradiation

All Individual Drugs Already Approved

Approved for 10 Other Conditions

This randomized phase III trial studies pelvic radiation therapy to see how well it works compared with vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with high-risk stage I or stage II endometrial cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Implant radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether pelvic radiation therapy alone is more effective than vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with endometrial cancer.

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Radiation + Chemotherapy for Uterine Cancer

This study is evaluating whether pelvic radiation therapy is better than vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with endometrial cancer.

My endometrial cancer is stage II with cervical invasion.

Your test results need to meet specific requirements to qualify.

I have had or will have a test for cancer cells in my abdomen as per GOG guidelines.

You have endometrial cancer that fits specific criteria based on its type, size, and location. You also need to have a certain level of blood cell counts, kidney and liver function, and performance status. You must sign a consent form and allow the release of your personal health information.

You need to have at least 100,000 platelets in a small amount of your blood.

Your bilirubin level must be less than or equal to 1.5 times the upper limit of normal.

My cancer is a rare type of uterine cancer, not the common endometrial cancer.

I have had a hysterectomy and possibly removal of both ovaries and fallopian tubes.

I may consider lymph node removal in my pelvic or para-aortic area.

My surgery can be done through a large incision or small incisions, depending on my surgeon's choice.

My cancer stage was determined using the FIGO 2009 system.

My cancer is confined to the uterus and has a specific cell type, with no cancer cells found in my abdomen.

My kidney function test shows I can clear more than 50 mL/min.

My nerve damage does not significantly affect my daily activities.

I've had a CT/MRI showing no signs of cancer spread if I didn't have certain surgeries.

My surgery can be open or minimally invasive, and it must be documented if lymph nodes were removed.

I have had a hysterectomy, and removal of both ovaries is highly recommended.

I am 18 or older and have 3 risk factors.

I have had radiation therapy for cancer in my abdomen or pelvis.

My cancer has spread beyond my uterus and cervix.

I cannot receive radiation therapy to my pelvis due to health reasons.

I have had non-surgical treatment for endometrial cancer.

My endometrial cancer is at an advanced stage (III or IV).

I am 70 or older with at least one risk factor or 50 or older with two risk factors.

You have signs of cancer spread in your lymph nodes or other parts of the body as seen in imaging tests.

I have not had any cancer except for non-melanoma skin cancer in the last 5 years.

My cancer is a specific type of endometrial carcinoma and fits certain risk categories.

My doctor took a sample from my abdomen to check for cancer.

Your alkaline phosphatase blood levels must not be more than 2.5 times the upper limit of normal.

I had a CT or MRI if I didn't have certain ovarian or lymph node surgeries.

You must have enough white blood cells called neutrophils.

Your blood creatinine level must be within the normal range for the hospital or clinic where the study is taking place.

Your SGOT level in the blood should be no more than 2.5 times the usual upper limit.

My cancer is aggressive or has spread to nearby vessels or deep into the muscle.

Paclitaxel

Pelvic Radiation Therapy

Vaginal Implant Radiation Therapy

The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591 in combination with ketoconazole and hydrocortisone against prostate cancer.

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

177Lu-J591 + Ketoconazole for Prostate Cancer

This study is evaluating whether a drug which targets a specific protein in the body may help treat prostate cancer.

My platelet count is below 150,000 or I have a known platelet disorder.

My blood clotting tests are abnormal, but I am on blood thinners.

I have had radiation therapy on more than a quarter of my bones.

I haven't taken any adrenal hormone inhibitors (except ketoconazole) in the last 4 weeks.

My prostate cancer was confirmed by a lab test and I've had surgery or radiotherapy.

I have not taken Finasteride or Dutasteride in the last 4 weeks.

I do not have serious heart, lung, brain, kidney, liver, or blood diseases that could affect my participation.

I was on corticosteroids but stopped or my condition worsened while on a stable dose.

I have not had blood or platelet transfusions in the last 4 weeks.

I have previously been treated with 89Strontium or 153Samarium.

I have used ketoconazole for prostate cancer treatment for more than a month.

Cedars-Sinai Clinical Trials 2022

Trials at this site

Is this your site?

Is this your site?